Granite Investment Partners LLC Reduces Position in ICU Medical, Inc. (NASDAQ:ICUI)

Granite Investment Partners LLC reduced its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 102,087 shares of the medical instruments supplier's stock after selling 2,215 shares during the quarter. Granite Investment Partners LLC owned approximately 0.42% of ICU Medical worth $15,841,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the business. State Street Corp raised its stake in ICU Medical by 9.3% during the 3rd quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier's stock worth $165,384,000 after buying an additional 77,506 shares during the period. Jane Street Group LLC raised its stake in shares of ICU Medical by 137.5% in the third quarter. Jane Street Group LLC now owns 28,729 shares of the medical instruments supplier's stock worth $5,235,000 after purchasing an additional 16,635 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in ICU Medical during the third quarter worth $247,000. XTX Topco Ltd bought a new position in ICU Medical during the 3rd quarter valued at $342,000. Finally, Barclays PLC grew its stake in shares of ICU Medical by 15.6% in the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier's stock worth $10,790,000 after acquiring an additional 8,010 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Stock Down 0.6 %

ICUI stock traded down $0.90 during midday trading on Tuesday, hitting $139.64. The stock had a trading volume of 148,529 shares, compared to its average volume of 269,288. ICU Medical, Inc. has a 52-week low of $93.36 and a 52-week high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The business has a 50-day moving average of $147.50 and a two-hundred day moving average of $160.47. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -30.56 and a beta of 0.86.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ICUI shares. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research report on Tuesday, April 8th. StockNews.com upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Friday, April 4th. Finally, Raymond James set a $97.00 price objective on ICU Medical in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $168.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.